# Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

> **NCT03245736** · PHASE2 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 5 (actual)

## Conditions studied

- Ovary Cancer
- Cervix Cancer
- Endometrium Cancer
- Bladder Cancer
- Prostate Cancer
- Esophagus Cancer
- Lung Cancer, Nonsmall Cell
- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Tisotumab Vedotin

## Key facts

- **NCT ID:** NCT03245736
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-23
- **Primary completion:** 2019-01-10
- **Final completion:** 2019-01-10
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2021-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03245736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03245736, "Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03245736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*